A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00037518

Enrollment

Registered

2002-05-20

Start date

2001-04-30

Completion date

Unknown

Last updated

2013-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism, Parathyroid Neoplasms

Keywords

Severe primary hyperparathyroidism, Parathyroid carcinoma

Brief summary

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Interventions

DRUGAMG 073

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; \* Abnormally elevated calcium levels above 12.5 mg/dL; \* Not be pregnant or nursing; \* Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.

Design outcomes

Primary

Measure	Time frame
Changes in serum calcium and PTH	—

Secondary

Measure	Time frame
Safety and tolerability of cinacalcet	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026